Head-To-Head Contrast: Titan Medical (NASDAQ:TMDIF) and InfuSystem (NYSE:INFU)

InfuSystem (NYSE:INFU) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Volatility & Risk

InfuSystem has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares InfuSystem and Titan Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Titan Medical	N/A	-82.31%	-51.47%

Insider and Institutional Ownership

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 11.4% of InfuSystem shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for InfuSystem and Titan Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	1	2	2	3.20
Titan Medical	0	0	0	0	0.00

InfuSystem presently has a consensus target price of $14.50, indicating a potential upside of 56.93%. Given InfuSystem’s stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Titan Medical.

Earnings and Valuation

This table compares InfuSystem and Titan Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$141.05 million	1.33	$870,000.00	$0.26	35.54
Titan Medical	$17.63 million	2.33	$6.95 million	$0.05	7.20

Titan Medical has lower revenue, but higher earnings than InfuSystem. Titan Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Summary

InfuSystem beats Titan Medical on 13 of the 15 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About Titan Medical

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.